Navigation Links
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Date:8/27/2007

TORONTO, Aug. 27 /PRNewswire/ -- Drug Royalty LP 2 (DRC) announced today the purchase of 25% of Enzon Pharmaceuticals, Inc.'s (ENZN) worldwide royalty interest in PEG-INTRON for $92.5M. DRC will also provide a $15M milestone payment in 2012 should certain royalty recognition levels be met. PEG-INTRON (peginterferon alpha-2b), is approved for the treatment of Hepatitis C and is marketed worldwide by Schering-Plough Corporation (SGP).

Speaking on behalf of DRC, Paul Kirkconnell, Managing Director, said: "DRC is very pleased to be working with Enzon Pharmaceuticals. We believe that PEG- INTRON is one of the most advanced medications to treat Hepatitis C on the market today." Kirkconnell added, "With access to significant capital and a long track record in completing royalty transactions, we take pride in meeting the needs of pharmaceutical companies such as Enzon."

About PEG-INTRON(R)

PEG-INTRON is a PEG-enhanced version of Schering-Plough's alpha interferon product, INTRON(R) A, which is used both as a monotherapy and in combination with REBETOL(R) (ribavirin) capsules for the treatment of chronic hepatitis C. Under Enzon's license agreement with Schering-Plough, Schering-Plough holds an exclusive worldwide license to PEG-INTRON, and Enzon receives royalties on worldwide sales of PEG-INTRON. Schering-Plough is responsible for all manufacturing, marketing, and development activities for PEG-INTRON. Enzon designed PEG-INTRON to allow for less frequent dosing and to yield greater efficacy, as compared to INTRON A. PEG-INTRON is marketed worldwide by Schering-Plough and its affiliates.

About Drug Royalty Corporation, Inc. (DRC)

Drug Royalty Corporation ("DRC") is a privately held investment management company, focused on the healthcare industry, with over $1 billion under management. DRC currently manages two funds: the Royalty Monetization Fund and the Structured Finance Fund.

Its Royalty Monetization Fund acquires existing roya
'/>"/>

SOURCE Drug Royalty Corporation, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Intarcia Therapeutics, Inc. delivered two presenta...s delivery of exenatide) program for the treatment...echnology Meeting in San Francisco, CA: ,, (Log...FTU126LOGO ) ,, Continuous Subcutaneous Deliv...e, HbA1c and Reduces Weight in a 28-day Phase 1b S...
(Date:11/5/2009)... DSM Pharmaceutical Products today announced that ... Saint Jean D,Illac, France, where DSM will be the...for Galenix commercial products on a global basis....s development opportunities co-marketing Galenix d...f Galenix in drug product development and clinical...
(Date:11/5/2009)...Call/ -- BioSpecifics Technologies Corp. (Nasdaq: ...rst-in-class collagenase-based products, today ann... ended September 30, 2009. ,, "We were extreme...s Arthritis Advisory Committee unanimously recomme...M) for the treatment of Dupuytren,s disease, and w...
(Date:11/5/2009)...ineSmith Partners has signed an initial agreement ...d that mimics the structure of natural cancellous ...products by SpineSmith,s Research and Development ...fold represents a significant advancement in techn...for the delivery of adult stem cells for skeletal ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 2DSM Pharmaceutical Products Forms Manufacturing Alliance With Galenix 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
... closing condition to merger with Raven ...ISCO, Calif., Dec. 20 VaxGen,Inc. (Pink Sheets: V... that,it has, along with Punk Ziegel and Company, ...on stock for quotation on the OTC Bulletin Board, ...the year under the symbol VXGN.,Further, VaxGen an...
...rma is pleased to announce the,fall conference lin...are,impacting the pharmaceutical industry today. T...tional and networking opportunities for Clinical,M... large to small,pharmaceutical, biotech and medica...on some of the featured events and highlights,from...
...Roche has Filed an IND With the US FDA for a ..., August 10 Genmab A/S (OMX: GEN),announced today...al New,Drug application (IND) with the US Food and...ed under the companies, collaboration. Genmab will... not influence Genmab,s,financial guidance for 200...
Other Biology Technology:VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 2VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 3VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board 4Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharma's Fall Line Up! 2Roche Files IND for Second Genmab Antibody 2
(Date:11/6/2009)...with their arboreal hosts. But new research sugges...of choice, the ants can get destructive to neighbo...ember issue of the American Naturalist , is the f...nd it reopens a centuries-old debate on the relati...in species of plants and trees have cozy relations...
(Date:11/5/2009)...ning grant in the amount of $2,756,719 by the Nati...uation Education and Research Training (IGERT) pro...to Kent State. The grant, which is funded under th...runs through 2014. , The grant funds an IGERT pr... sensing (EARS). The purpose of the program is to ...
(Date:11/4/2009)... hold the power to help militaries and munitions m...c waste on test sites. , Compounds known as nitr...rld War II and have been used in military munition...ten used to propel tank shells and act like a more... knowledge of their environmentally harmful effect...
Breaking Biology News(10 mins):Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Genomic research will enable greener cleanup of military explosive test sites 2Switching early breast cancer patients to exemestane improves long term survival 57884 1Switching early breast cancer patients to exemestane improves long term survival 57884 2Prince Albert II of Monaco Foundation helps fund Field Museum conservation efforts in Peru 10013 1Prince Albert II of Monaco Foundation helps fund Field Museum conservation efforts in Peru 10013 2Julio Palmaz to Present at the 2009 TCT Conference 57879 1Julio Palmaz to Present at the 2009 TCT Conference 57879 2
...y Assistance (AOA), a comprehensive, multi-faceted..."cap" on out-of-pocket co-payments for cancer pati...h AOA, patients who are uninsured, underinsured, o...l receive help obtaining financial support for Amg...ng cancer is expensive and our industry needs to f...
...ully so your buddy can get some tail may seem like...rds, it also gives a fascinating peek into hard-wi...hed lizards spend their year on earth looking to r...evolution. An article in the May 9 edition of the ...ovides the first genetic evidence of a trait that ...
...oteins in the brains of individuals addicted to co...nd mechanisms that may one day lead to new treatme...rted in the current issue of Molecular Psychiatry,...mounts of 50 proteins and point to profound change...se, said Scott E. Hemby, Ph.D., of Wake Forest Uni...
Other Biology News:Amgen introduces comprehensive financial assistance programs for cancer patients 2Nice guys do finish first in lizards' evolutionary race 2High-tech research shows cocaine changes proteins and brain function 2
Finnpipette BioControl Multichannel, 8 Channel 5-50ul from Thermo Scientific
Acl I (Psp1406 I) from New England Biolabs
Mouse Anti-Human Cystatin A Monoclonal Antibody, Unconjugated, Clone 224705 from R&D Systems
Acc I from Takara Mirus Bio
Biology Products: